A therapy that retrains the body’s immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission.
White blood cells were taken from patients with leukaemia, modified in the lab and then put back.
But the data has not been published or reviewed and two patients are said to have died from an extreme immune response.
Experts said the trial was exciting, but still only “a baby step.”
The news bubbled out of the American Association for the Advancement of Science’s annual meeting in Washington DC.
The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live.
He told the conference that: “The early data is unprecedented.”
In the trial, cells from the immune system called killer t-cells were taken out of dozens of patients. The cells normally act like bombs destroying infected tissue.
The researchers genetically modified the t-cells to engineer a new targeting mechanism – with the technical name of chimeric antigen receptors – to target acute lymphoblastic leukaemia.
Prof Riddell told the BBC: “Essentially what this process does is, it genetically reprograms the T-cell to seek out and recognise and destroy the patient’s tumour cells.
“[The patients] were really at the end of the line in terms of treatment options and yet a single dose of this therapy put more than ninety percent of these patients in complete remission where we can’t detect any of these leukaemia cells.”
But one cancer expert told me they still felt in the dark on the full significance of the study, as the data is not available.
Learn more: Excitement at new cancer treatment
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Cancer Immunotherapy Market 2020 Clinical Survey Report – Roche, Bayer, Eli Lilly, Merck, Novartison February 1, 2020 at 12:39 am
The Cancer Immunotherapy Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants ...
- Enhancing cancer immunotherapy with nanomedicineon January 31, 2020 at 5:49 am
Therapeutic targeting of the immune system in cancer is now a clinical reality and marked successes have been achieved, most notably through the use of checkpoint blockade antibodies and chimeric ...
- Neoadjuvant checkpoint blockade for cancer immunotherapyon January 30, 2020 at 10:57 am
1 Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. 2 Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, ...
- Cancer Immunotherapy Market is Expected to Garner Higher Revenues between 2020-2025on January 30, 2020 at 9:55 am
New York, January 30, 2020: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled ...
- Immunotherapy called ‘the future of cancer care,’ but not without risks, costs: Health Matterson January 30, 2020 at 8:27 am
Q: What is immunotherapy, and what kinds of cancer can it treat? A: Immunotherapy is a cancer treatment that activates a patient’s immune system to identify and destroy diseases such as cancer.
- Cancer Immunotherapy Market Size to Hit US$ 115.4 Bn by 2026on January 30, 2020 at 7:38 am
The global cancer immunotherapy market is expected to grow at a noteworthy CAGR of around 10.6% during the forecast period 2019 to 2026 LOS ANGELES, Jan. 30, 2020 /PRNewswire/ -- The Cancer ...
- Global cancer immunotherapy market is expected to grow with a CAGR of 15.12% over the forecast period from 2019-2025on January 28, 2020 at 9:20 am
The report on the global cancer immunotherapy market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global cancer immunotherapy market to grow ...
- Cancer: Using copper to boost immunotherapyon January 25, 2020 at 3:17 am
Importantly, the tumors did not return after the treatment ceased. Share on Pinterest Could copper compounds combined with immunotherapy help combat cancer? According to the World Health Organization, ...
- HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animalson January 24, 2020 at 6:40 am
The paper highlights the candidate’s ability to target and shrink HPV motivated tumors in both animal studies and human blood samples.
- OncoCyte Enters Into The Cancer Immunotherapy Field With The Acquisition Of Insight Geneticson January 23, 2020 at 1:46 am
This acquisition enables OCX to enter into the oncological immunotherapy field. IG has a rich menu of therapeutic panels among which the "Immune Modulation" (IM score) stands out, a genetic test to ...
via Bing News